Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KGS Tablet is an Ayurvedic herbal formulation developed by Kottakkal Arya Vaidya Sala, primarily derived from the plant *Cyanthillium cinereum* (commonly known as Sahadevi or *Vernonia cinerea*). It is formulated as an oral tablet and is utilized for its reported anti-inflammatory and anticancer properties. Research conducted by the developer focuses on phytochemical analysis and observational studies rather than conventional Phase 1-3 clinical trials. The therapeutic effects are attributed to the natural bioactive compounds present in the herbal extract, which have shown activity in preliminary studies against inflammatory conditions and various cancer cell lines. As a traditional medicine, it is part of the company's research and development pipeline aimed at validating traditional Ayurvedic treatments through modern scientific methods.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KGS Tablet.